OverviewSuggest Edit

Alimera Sciences is a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company is presently focused on diseases affecting the back of the eye, or retina, because these diseases are not well treated with current therapies and will affect millions of people in our aging populations. Its commitment to retina specialists and their patients is manifest in our product and development portfolio designed to treat early- and late-stage diseases such as diabetic macular edema (DME), wet and dry age-related macular degeneration and retinal vein occlusion.

TypePublic
Founded2003
HQAlpharetta, US
Websitealimerasciences.com
Employee Ratings4.1

Latest Updates

Employees (est.) (Feb 2019)118(-6%)
Revenue (FY, 2018)$47 M(+31%)
Share Price (Mar 2019)$1.2

Key People/Management at Alimera Sciences

Ken Greene

Ken Greene

CSO
Susan Caballa

Susan Caballa

Sr. Vice President, Regulatory & Medical Affairs
Philip Ashman

Philip Ashman

SVP & European Managing Director
Rick Eiswirth

Rick Eiswirth

President & CFO
Dave Holland

Dave Holland

SVP of Sales & Marketing
Show more

Alimera Sciences Office Locations

Alimera Sciences has offices in Alpharetta, Berlin, Hampshire and Lisbon
Alpharetta, US (HQ)
6120 Windward Pkwy #290
Berlin, DE
21 Cicerostraße
Hampshire, GB
Wellesley Rd
Show all (4)
Report incorrect company information

Alimera Sciences Financials and Metrics

Alimera Sciences Revenue

Alimera Sciences's revenue was reported to be $46.97 m in FY, 2018
USD

Revenue (FY, 2018)

47.0m

Net income (FY, 2018)

(16.4m)

EBIT (FY, 2018)

(9.7m)

Market capitalization (18-Mar-2019)

82.3m

Closing stock price (18-Mar-2019)

1.2

Cash (31-Dec-2018)

13.0m

EV

107.2m
Alimera Sciences's current market capitalization is $82.3 m.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Revenue

1.9m8.4m22.4m34.3m35.9m47.0m

Revenue growth, %

350%166%53%

Cost of goods sold

1.9m

Gross profit

9.0k
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Revenue

758.0k2.1m2.2m2.4m3.9m5.8m6.9m5.8m9.6m8.3m6.6m10.4m9.8m9.8m10.9m11.1m

Cost of goods sold

57.0k564.0k376.0k

Gross profit

701.0k1.5m1.8m

Gross profit Margin, %

92%73%83%
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Cash

12.6m76.7m31.1m31.0m24.1m13.0m

Accounts Receivable

500.0k850.0k9.8m13.8m11.4m17.3m

Inventories

1.8m3.2m1.6m446.0k1.5m2.4m

Current Assets

18.6m83.3m45.2m47.4m39.3m34.8m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Cash

23.1m41.3m42.0m61.4m61.3m48.1m39.3m23.9m16.6m33.9m26.7m26.9m25.6m

Accounts Receivable

464.0k1.3m1.0m1.1m3.4m7.7m9.4m9.1m13.3m13.4m10.8m13.6m13.5m

Inventories

3.0m1.2m1.4m1.7m2.1m1.6m1.7m1.4m1.2m913.0k802.0k1.1m1.7m

Current Assets

30.1m46.5m47.5m67.3m70.3m61.1m53.4m37.2m34.7m51.6m40.5m44.3m43.6m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Net Income

(46.2m)(35.9m)(30.6m)(33.2m)(22.0m)(16.4m)

Depreciation and Amortization

138.0k659.0k2.6m2.8m2.7m2.6m

Inventories

(1.4m)206.0k(386.0k)1.0m(1.1m)(933.0k)

Accounts Payable

(259.0k)3.0m(487.0k)1.1m644.0k556.0k
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Net Income

(31.5m)(20.8m)(19.6m)(26.7m)(9.8m)(18.4m)(19.9m)(11.1m)(18.0m)(27.2m)(6.7m)(9.5m)(14.8m)(7.7m)(11.7m)(15.1m)

Depreciation and Amortization

101.0k36.0k69.0k151.0k558.0k1.2m1.9m689.0k1.4m2.1m666.0k1.3m2.0m649.0k1.3m1.9m

Inventories

(2.2m)548.0k400.0k(9.0k)(455.0k)(16.0k)(88.0k)164.0k301.0k612.0k(361.0k)(719.0k)(1.3m)299.0k(651.0k)(250.0k)

Accounts Payable

717.0k111.0k122.0k1.3m272.0k(1.2m)(1.4m)(1.5m)264.0k(2.1m)(1.1m)572.0k98.0k(992.0k)167.0k(779.0k)
USDY, 2018

EV/EBIT

-11.1 x

EV/CFO

-9.3 x

Financial Leverage

19.9 x
Show all financial metrics
Report incorrect company information

Alimera Sciences Online and Social Media Presence

Embed Graph
Report incorrect company information

Alimera Sciences News and Updates

Retinal Drugs And Biologics Market 2019: Booming Worldwide by Key Players like Alimera Sciences, Janssen Biotech, Inc., F. Hoffmann-La Roche Ltd., Genzyme Corporation, Ocular Therapeutix, Inc.

The retina is a delicate and sensitive part of the human eye. It is helpful in processing and receiving the light and converts them into neural signals and passes them to the brain for the activities that are done visually. The retinal health disorders include age-related macular degeneration, infec…

Retinal Drugs and Biologics Global Market 2019 Top Key Players – ALLERGAN,  AbbVie , Alimera Sciences,  Janssen Biotech,  Swedish Orphan Biovitrum and Forecast to 2023

Wiseguyreports.Com Added New Market Research Report On -“Retinal Drugs and Biologics Market 2019 Key Players, Applications and Future Demand Forecast to 2023 ”. Posted via Industry Today. Follow us on Twitter @IndustryToday

Alimera Sciences Announces Nine Clinical Presentations and a Sponsored Symposium at 18th EURETINA Congress

ATLANTA, Sept. 17, 2018 /PRNewswire/ -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a leader in commercialization and development of prescription ophthalmic pharmaceuticals, today announced that nine clinical presentations from real world ILUVIEN® usage in Europe and the U.S. will be ...

Alimera Sciences Announces Three Podium Presentations for ILUVIEN® to be Presented at 2018 Retina Society's Annual Meeting

ATLANTA, Sept. 13, 2018 /PRNewswire/ -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, today announced that two presentations will be delivered, and one poster presented, on ILUVIEN® during the ...

Global Diabetic Macular Edema Treatment Market 2018-2022 - Key Vendors are Allergan Alimera Sciences, Bausch Health, F. Hoffmann-La Roche & Regeneron Pharmaceuticals

DUBLIN, Sept 11, 2018 /PRNewswire/ -- The "Global Diabetic Macular Edema Treatment Market 2018-2022" report has been added to ResearchAndMarkets.com's offering. The Global Diabetic Macular Edema Treatment Market to grow at a CAGR of 1.45% during the period 2018-2022. Global Diabetic...

Alimera Sciences Announces Exchange of Series B Preferred Stock for Newly Issued Series C Preferred Stock

ATLANTA, Sept. 4, 2018 /PRNewswire/ -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, today announced that it has closed an agreement with Deerfield Management and certain of its affiliates...
Show more
Report incorrect company information

Alimera Sciences Blogs

Alimera Sciences Reports Record Fourth Quarter and 2018 Results

Fourth Quarter 2018 Highlights Fourth quarter 2018 consolidated net revenue up 66% International segment revenue increased 138% over the prior year period Net Loss of $1.2 million vs. Net Loss of $7.2 million during 4Q17 Positive Adjusted EBITDA of $2.4 million vs.

Alimera Sciences Announces Approval For ILUVIEN® in Lebanon

Lebanon will be the second Middle Eastern country to approve ILUVIEN   ATLANTA, February 5, 2018 – Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, today announced that product registration has been

Alimera Sciences to Report Fourth Quarter and Full Year 2018 Results on February 18, 2019

ATLANTA, February 4th, 2019 – Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, today announced that it will release its financial results for the three and twelve month periods ended December 31, 2018

Alimera Sciences Affirms Record 2018 Revenues

Anticipates 2018 GAAP Net Revenue in Excess of $45 Million ATLANTA, January 7, 2019 – Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, today affirmed that it expects record annual 2018 and fourth quarter

Alimera Sciences Announces Pricing Approval For ILUVIEN® in the U.A.E.

Alimera Sciences Announces Pricing Approval For ILUVIEN® in the U.A.E. Jonathan.Lorin… Sun, 12/16/2018 - 22:08 Alimera Sciences Announces Pricing Approval For ILUVIEN® in the U.A.E. Dec 17, 2018 This release is a backfill from a News Wire …

Alimera Sciences Appoints Rick Eiswirth as Chief Executive Officer

Alimera Sciences Appoints Rick Eiswirth as Chief Executive Officer Neil.Lawrence@… Thu, 11/29/2018 - 07:37 Alimera Sciences Appoints Rick Eiswirth as Chief Executive Officer Nov 29, 2018 This release is a backfill from a News Wire General…
Show more

Alimera Sciences Frequently Asked Questions

  • When was Alimera Sciences founded?

    Alimera Sciences was founded in 2003.

  • Who are Alimera Sciences key executives?

    Alimera Sciences's key executives are Ken Greene, Susan Caballa and Philip Ashman.

  • How many employees does Alimera Sciences have?

    Alimera Sciences has 118 employees.

  • What is Alimera Sciences revenue?

    Latest Alimera Sciences annual revenue is $47 m.

  • What is Alimera Sciences revenue per employee?

    Latest Alimera Sciences revenue per employee is $398.1 k.

  • Who are Alimera Sciences competitors?

    Competitors of Alimera Sciences include Reata Pharmaceuticals, Ironwood Pharmaceuticals and Biogen.

  • Where is Alimera Sciences headquarters?

    Alimera Sciences headquarters is located at 6120 Windward Pkwy #290, Alpharetta.

  • Where are Alimera Sciences offices?

    Alimera Sciences has offices in Alpharetta, Berlin, Hampshire and Lisbon.

  • How many offices does Alimera Sciences have?

    Alimera Sciences has 4 offices.